Particle Beam Radiation Therapy for Skull Base Sarcomas

Yang, Jing; Hu, Weixu; Guan, Xiyin; Hu, Jiyi; Gao, Jing; Qiu, Xianxin; Huang, Qingting; Zhang, Wenna; Kong, Lin; Lu, Jiade J.

doi:10.3389/fonc.2020.01368

Cited by 3 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 45 radiation-naïve patients in this study, 2-y PFS and OS were 62.9% and 80.2%, respectively ( 38 ).…”

Section: Chondrosarcomas and Other Sarcomasmentioning

confidence: 87%

“…Chondrosarcoma is perhaps the most common histotype of sarcoma starting at the skull base, but it is not the only one. Literature on the use of PRT for the treatment of the base of skull sarcomas other than chordoma and chondrosarcoma, which are usually more aggressive, is scarce ( 37 , 38 ).…”

Section: Chondrosarcomas and Other Sarcomasmentioning

confidence: 99%

“…Few data concerning other types of skull base sarcomas are reported in case series or in inclusive studies of different sarcomatous histologies, such as the study by Yang and colleagues published in 2020. In this study, the authors reported the clinical outcomes of 62 patients with skull base bone or soft-tissue sarcomas (chordoma excluded) treated with PRT (both proton and carbon ion) as primary RT or re-RT for relapse ( 38 ).…”

Section: Chondrosarcomas and Other Sarcomasmentioning

confidence: 99%

See 2 more Smart Citations

The role of particle radiotherapy in the treatment of skull base tumors

et al. 2023

View full text Add to dashboard Cite

The skull base is an anatomically and functionally critical area surrounded by vital structures such as the brainstem, the spinal cord, blood vessels, and cranial nerves. Due to this complexity, management of skull base tumors requires a multidisciplinary approach involving a team of specialists such as neurosurgeons, otorhinolaryngologists, radiation oncologists, endocrinologists, and medical oncologists. In the case of pediatric patients, cancer management should be performed by a team of pediatric-trained specialists. Radiation therapy may be used alone or in combination with surgery to treat skull base tumors. There are two main types of radiation therapy: photon therapy and particle therapy. Particle radiotherapy uses charged particles (protons or carbon ions) that, due to their peculiar physical properties, permit precise targeting of the tumor with minimal healthy tissue exposure. These characteristics allow for minimizing the potential long-term effects of radiation exposure in terms of neurocognitive impairments, preserving quality of life, and reducing the risk of radio-induced cancer. For these reasons, in children, adolescents, and young adults, proton therapy should be an elective option when available. In radioresistant tumors such as chordomas and sarcomas and previously irradiated recurrent tumors, particle therapy permits the delivery of high biologically effective doses with low, or however acceptable, toxicity. Carbon ion therapy has peculiar and favorable radiobiological characteristics to overcome radioresistance features. In low-grade tumors, proton therapy should be considered in challenging cases due to tumor volume and involvement of critical neural structures. However, particle radiotherapy is still relatively new, and more research is needed to fully understand its effects. Additionally, the availability of particle therapy is limited as it requires specialized equipment and expertise. The purpose of this manuscript is to review the available literature regarding the role of particle radiotherapy in the treatment of skull base tumors.

show abstract

“…Among the 45 radiation-naïve patients in this study, 2-y PFS and OS were 62.9% and 80.2%, respectively ( 38 ).…”

Section: Chondrosarcomas and Other Sarcomasmentioning

confidence: 87%

Section: Chondrosarcomas and Other Sarcomasmentioning

confidence: 99%

Section: Chondrosarcomas and Other Sarcomasmentioning

confidence: 99%

See 1 more Smart Citation

The role of particle radiotherapy in the treatment of skull base tumors

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A total of 62 patients with SBS received PBT and CIRT at the SPHIC between July 2014 and May 2019 ( 46 ). With a median follow-up of 20.4 (range 2.73–91.67) months, the 2-year OS and LRFS were 80.2% and 80.2%, respectively ( 39 ).…”

Section: Clinical Practicesmentioning

confidence: 99%

Flourish of Proton and Carbon Ion Radiotherapy in China

Jiang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Proton and heavy ion therapy offer superior relative biological effectiveness (RBE) in the treatment of deep-seated tumors compared with conventional photon radiotherapy due to its Bragg-peak feature of energy deposition in organs. Many proton and carbon ion therapy centers are active all over the world. At present, five particle radiotherapy institutes have been built and are receiving patient in China, mainly including Wanjie Proton Therapy Center (WPTC), Shanghai Proton Heavy Ion Center (SPHIC), Heavy Ion Cancer Treatment Center (HIMM), Chang Gung Memorial Hospital (CGMH), and Ruijin Hospital affiliated with Jiao Tong University. Many cancer patients have benefited from ion therapy, showing unique advantages over surgery and chemotherapy. By the end of 2020, nearly 8,000 patients had been treated with proton, carbon ion or carbon ion combined with proton therapy. So far, there is no systemic review for proton and carbon ion therapy facility and clinical outcome in China. We reviewed the development of proton and heavy ion therapy, as well as providing the representative clinical data and future directions for particle therapy in China. It has important guiding significance for the design and construction of new particle therapy center and patients’ choice of treatment equipment.

show abstract

Application of Carbon Ion and Its Sensitizing Agent in Cancer Therapy: A Systematic Review

Wang

Chen

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Carbon ion radiation therapy (CIRT) is the most advanced radiation therapy (RT) available and offers new opportunities to improve cancer treatment and research. CIRT has a unique physical and biological advantage that allow them to kill tumor cells more accurately and intensively. So far, CIRT has been used in almost all types of malignant tumors, and showed good feasibility, safety and acceptable toxicity, indicating that CIRT has a wide range of development and application prospects. In addition, in order to improve the biological effect of CIRT, scientists are also trying to investigate related sensitizing agents to enhance the killing ability of tumor cells, which has attracted extensive attention. In this review, we tried to systematically review the rationale, advantages and problems, the clinical applications and the sensitizing agents of the CIRT. At the same time, the prospects of the CIRT in were prospected. We hope that this review will help researchers interested in CIRT, sensitizing agents, and radiotherapy to understand their magic more systematically and faster, and provide data reference and support for bioanalysis, clinical medicine, radiotherapy, heavy ion therapy, and nanoparticle diagnostics.

show abstract

Particle Beam Radiation Therapy for Skull Base Sarcomas

Cited by 3 publications

References 33 publications

The role of particle radiotherapy in the treatment of skull base tumors

The role of particle radiotherapy in the treatment of skull base tumors

Flourish of Proton and Carbon Ion Radiotherapy in China

Application of Carbon Ion and Its Sensitizing Agent in Cancer Therapy: A Systematic Review

Contact Info

Product

Resources

About